The purpose of this report is to review the clinical trials used to evaluate TAVR in patients who are at higher risk for sAVR. The clinical evidence base includes both prospective registries and randomized clinical trials. Future trial designs evaluating TAVR in intermediate populations will also be discussed.

" /> The purpose of this report is to review the clinical trials used to evaluate TAVR in patients who are at higher risk for sAVR. The clinical evidence base includes both prospective registries and randomized clinical trials. Future trial designs evaluating TAVR in intermediate populations will also be discussed.

"> Article Full Text – Methodist Journal
Methodist Journal

IN THIS ISSUE

Nutritional Supplements and the Heart

Vol 15, Issue 3 (2019)


FEATURED GUEST EDITOR

ISSUE INTRO

Dietary Supplements: Facts and Fallacies

See More
RECOGNITIONS

Drs. Raizner and Cooke Take the Lead in Special Issue on Supplements

See More

REVIEW ARTICLES See More

Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids

Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment

Coenzyme Q10

Red Yeast Rice for Hypercholesterolemia

Inorganic Nitrate Supplementation for Cardiovascular Health

Vitamin D and Calcium Supplements: Helpful, Harmful, or Neutral for Cardiovascular Risk?

Cardiovascular Risk of Proton Pump Inhibitors

Advanced Cardiac Imaging for Complex Adult Congenital Heart Diseases

CASE REPORTS See More

A Rare Case of Pancreatitis-Induced Thrombosis of the Aorta and Superior Mesenteric Artery

Anomalous Origin of the Right Coronary Artery from the Left Main Coronary Artery in the Setting of Critical Bicuspid Aortic Valve Stenosis

Simultaneous Transfemoral Mitral and Tricuspid Valve in Ring Implantation: First Case Report with Edwards Sapien 3 Valve

Uneventful Follow-Up 2 Years after Endovascular Treatment of a High Flow Iatrogenic Aortocaval Fistula Causing Pulmonary Hypertension and Right Heart Failure

MUSEUM OF HMH MULTIMODALITY IMAGING CENTER See More

Snoopy’s Heart: A Case of Complete Congenital Absence of the Pericardium

CLINICAL PERSPECTIVES See More

POINTS TO REMEMBER

Herbal Nephropathy

EXCERPTA

Rolling the Dice on Red Yeast Rice

POINTS TO REMEMBER

The Kidney in Congenital Cyanotic Heart Disease

EXCERPTA

Talking Statins with Antonio Gotto

EDITORIALS

Letter to the Editor in Response to “Cardiac Autonomic Neuropathy in Diabetes Mellitus”

Vol 8, Issue 2 (2012)

Article Full Text

REVIEW ARTICLES

Clinical Studies Assessing Transcatheter Aortic Valve Replacement

Jump to:
Article Citation:

Shaheena Raheem and Jeffrey J. Popma. Clinical Studies Assessing Transcatheter Aortic Valve Replacement. Methodist DeBakey Cardiovascular Journal: April 2012, Vol. 8, No. 2, pp. 13-18.

doi: https://doi.org/10.14797/mdcj-8-2-13

Abstract

Degenerative aortic stenosis is the most common acquired valvular heart disease in the developed countries, affecting more than 300,000 people in the United States alone.1 Symptoms of aortic stenosis are latent until there is critical narrowing of the aortic valve that results in left ventricular hypertrophy, increased left ventricular diastolic pressure and left ventricle mass, and increased myocardial oxygen demand causing subendocardial ischemia.2 Once symptoms develop, the prognosis changes dramatically unless the aortic stenosis is corrected.2

Surgical aortic valve replacement (sAVR) is the recommended therapy for patients with symptomatic aortic stenosis. The most recent American College of Cardiology and American Heart Association (ACC/AHA) guidelines for sAVR are found in Table 1.3 It is important to note that none of these recommendations are based on evidence from large-scale, randomized clinical trials but instead rely on the expert opinion of experienced clinicians. The Society for Thoracic Surgery Predicted Risk of Mortality (STS-PROM) has been used to estimate 30-day mortality operative risk. Other surgical risk scores, such as the logistic EuroSCORE, while correlated with overall prediction of risk, are poorly calibrated to estimate precise sAVR mortality rates.4

Many patients cannot undergo sAVR due to excessive surgical risk, including porcelain aorta,5, 6 hostile mediastinum, severe lung or liver disease, frailty, renal failure,7-9 advanced age, and prior CABG,10 among other factors,11, 12 many of which are not included in current surgical risk assessment algorithms. In patients who are deemed unsuitable for sAVR due to comorbidities, transcatheter aortic valve replacement (TAVR) has been used as an alternative to relieve symptoms and extend life. Almost 50,000 patients have been treated worldwide with one of the two commercially approved TAVR devices, including the balloonexpandable Edwards SAPIEN Transcatheter Heart Valve (Edwards LifeSciences, Irvine, California) and the self-expanding CoreValve Revalving System (Medtronic, Minneapolis, Minnesota). A number of additional transfemoral and transapical devices are under evaluation.

The purpose of this report is to review the clinical trials used to evaluate TAVR in patients who are at higher risk for sAVR. The clinical evidence base includes both prospective registries and randomized clinical trials. Future trial designs evaluating TAVR in intermediate populations will also be discussed.

Keywords
transcatheter aortic valve replacement , surgical aortic valve replacement , TAVR , TAVI , aortic stenosis , Edwards SAPIEN Transcatheter Heart Valve , EuroSCORE , SOURCE registry , PARTNER trial , Medtronic CoreValve , SURTAVI trial

Add Comments

Please login to dialogue with author.

Comments